ClinicalTrials HQ

Cypress

Cypress

Cypress, Texas, United States

67 results · Page 1 of 3

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNeoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 32026-10-09NCT04181060
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventArterial Occlusive Diseases, Body Weight, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, chronic renal failure syndrome, diabetes mellitus, endocrine system disorder, glucose metabolism disease, hypertensive disorder, kidney disorder, kidney failure, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus, urinary system disorder, vascular disorderRecruitingPhase 22026-10-08NCT07783802
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 22026-10-08NCT07033494
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseAlzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-10-08NCT07011745
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor FluctuationsDyskinesias, Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathyRecruitingPhase 22026-10-06NCT07432958
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's DiseaseAlzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 22026-10-06NCT06808984
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaHypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderActive, not recruitingPhase 32026-10-06NCT06664619
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaAirway Obstruction, Dyspnea, Hypersensitivity, Immediate, Pathological Conditions, Signs and Symptoms, Respiration Disorders, Respiratory Hypersensitivity, Respiratory Sounds, Signs and Symptoms, Signs and Symptoms, Respiratory, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory failure, respiratory system disorderRecruitingPhase 22026-10-05NCT06977581
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerNeoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinomaRecruitingPhase 32026-10-05NCT06524544
ACP-204 in Adults With Alzheimer's Disease PsychosisHallucinations, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nervous system disorder, perceptual disordersRecruitingPhase 2 / Phase 32026-10-05NCT06159673
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2+ Breast CancerRecruitingPhase 32026-10-02NCT06876714
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Functioncardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-02NCT06307652
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heartcardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-01NCT06935370
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasisbronchial disorder, bronchiectasis, respiratory system disorderRecruitingPhase 32026-10-01NCT06872892
To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of TreatmentChronic Disease, Disease Attributes, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bronchial disorder, bronchitis, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder, respiratory tract infectious disorderRecruitingPhase 22026-09-30NCT07684820
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)Bronchial Spasm, Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 32026-09-30NCT07645248
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Studybone disorder, lumbar spinal stenosis, musculoskeletal system disorder, spinal stenosis, vertebral column disorderRecruitingNot stated2026-09-30NCT03072927
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisLewy Body Dementia PsychosisRecruitingPhase 32026-09-29NCT07095465
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisLewy Body Dementia PsychosisRecruitingPhase 22026-09-29NCT07029581
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseaseAlzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 22026-09-29NCT06540833
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Psychosis Associated With Alzheimer's DiseaseRecruitingPhase 32026-09-29NCT05980949
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic DermatitisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorderRecruitingPhase 22026-09-28NCT06947993
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)Alzheimer disease, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathyRecruitingPhase 32026-09-28NCT06937229
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseaseArterial Occlusive Diseases, Embolism and Thrombosis, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, peripheral arterial disease, peripheral vascular disease, thrombotic disease, vascular disorderRecruitingPhase 32026-09-25NCT07318610
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeChronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorderRecruitingPhase 32026-09-22NCT07190209